FDA
-
-
-
-
-
-
-
Cytodyn Inc. (CYDY) Announces President Takes Medical Leave of Absence
-
-
-
-
-
-
-
Cytodyn Inc. (CYDY) Resolves Legal Dispute with Ex Chief Medical Officer
-
-
-
-
-
-
-
CytoDyn to Hold Webcast and Live Q/A on January 13
-
-
-
-
-
-
-
CytoDyn to Hold Webcast and Live Q/A on December 14
-
-
-
-
-
-
-
Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
-
-
-
-
-
-
-
CytoDyn Announces Cancer Update: 12-month Analysis of 28 mTNBC Patients Receiving Leronlimab Suggests an Increase of 3600% in 12-month OS in 75% of Patients with a Lower Level of Circulating Cells Aft
-
-
-
-
-
-
-
Group of CytoDyn Stockholders Comments on Delaware Court Decision
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

